Eikon Therapeutics, Inc. (NASDAQ:EIKN)
| Market Cap | 395.75M-49.7% |
| Revenue (ttm) | 0 |
| Net Income | -322.16M |
| EPS | -4.63 |
| Shares Out | 54.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 178,467 |
| Open | 7.48 |
| Previous Close | 7.54 |
| Day's Range | 7.25 - 7.74 |
| 52-Week Range | 7.02 - 17.40 |
| Beta | 0.94 |
| Analysts | Sell |
| Price Target | 5.00(-31.60%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About EIKN
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$EIKN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in EIKN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EIKN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EIKN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New EIKN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EIKN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in EIKN
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $6.90M |
| IWMiShares Russell 2000 ETF | $6.13M |
| VXFVanguard Extended Market ETF | $2.52M |
| IWOiShares Russell 2000 Growth ETF | $1.54M |
| VTWOVanguard Russell 2000 ETF | $1.31M |
| SCHASchwab U.S. Small-Cap ETF | $1.13M |
Estimated from each fund’s disclosed top holdings × AUM
EIKN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from EIKN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score